Clinical trials
Epilepsy trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2016 | 5 |
| 2017 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Enrolling by invitation | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Danish Headache Center | 5 |
| UCB Pharma | 3 |
| University of Aarhus | 3 |
| Biohaven Therapeutics Ltd. | 2 |
| Eisai Inc. | 2 |
| Eisai Limited | 2 |
| Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2 |
| Aarhus University Hospital | 1 |
| Danish Dementia Research Centre | 1 |
| Duke University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsy | 38 |
| Seizures | 12 |
| Migraine Disorders | 6 |
| Drug Resistant Epilepsy | 4 |
| Headache | 4 |
| Epilepsies, Myoclonic | 3 |
| Brain Diseases | 2 |
| Epilepsies, Partial | 2 |
| Migraine with Aura | 2 |
| Alzheimer Disease | 1 |
Trials
Showing 26 to 38 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.